Angiodynamics receives fda clearance for the nanoknife® system for prostate tissue ablation

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received u.s. food and drug administration (fda) 510(k) clearance for the nanoknife system for prostate tissue ablation. the company received clearance for the nanoknife system for prostate tissue ablation follow.
ANGO Ratings Summary
ANGO Quant Ranking